Business Context and Reporting Period
Company: Passage Bio, Inc. (PASG)
Filing Type: Form 8-K (Current Report)
Date: April 20, 2026
Context: The filing discloses updated interim data from the Phase 1/2 upliFT-D clinical trial for PBFT02 (treating frontotemporal dementia caused by progranulin deficiency), regulatory feedback from the FDA, and the initiation of a strategic review process to maximize shareholder value.
Key Financial Metrics
This filing is a current report regarding clinical and strategic updates. It does not provide specific financial statements, revenue, profit, cash flow, margins, debt, or liquidity figures. The text references "financial challenges" regarding future trial designs but does not quantify the company's current financial position.
Material Changes and Clinical Updates
Clinical Data (PBFT02 for FTD-GRN)
- Biomarkers: Treated patients (CDR score 1) showed a 64% reduction in whole brain atrophy and a 54% reduction in frontotemporal cortex atrophy at 12 months compared to natural history data.
- Neurofilament Light Chain (NfL): Treated patients stabilized plasma NfL levels (average reduction of 1.0 pg/mL), whereas untreated patients saw an average increase of 13.5 pg/mL.
- Progranulin (PGRN) Levels: Dose 1 (4.5e13 genome copies) increased CSF PGRN from below 3 ng/mL to a mean of 22.8 ng/mL at 12 months and 24.2 ng/mL at 18 months. Dose 2 achieved comparable levels at six months.
- Safety: No new treatment-related serious adverse events (SAEs) reported since the last update. Previously disclosed SAEs included venous sinus thrombosis (n=2) and hepatotoxicity (n=1). No dorsal root ganglion toxicity was observed.
Regulatory Update
- The FDA indicated that a randomized controlled registrational study design is required for PBFT02 in the FTD-GRN indication.
- The Company is evaluating next steps due to the ethical, logistical, and financial challenges of conducting such a trial.
Corporate Update
- Passage Bio has initiated a review of strategic alternatives, which may include mergers, acquisitions, reverse mergers, asset sales, partnerships, or licensing.
- Advisor: Wedbush PacGrow has been engaged to assist in the strategic review.
Guidance, Outlook, and Risks
Outlook: The Company is assessing the feasibility of a randomized controlled trial following FDA feedback. The strategic review process is underway with no assurance of a transaction.
Risks and Contingencies:
- Uncertainty regarding the ability to identify and consummate a strategic alternative.
- Regulatory risks, including potential delays or requirements for additional studies.
- Clinical trial risks, including the possibility that early-stage results may not be replicated in later stages.
- Dependence on third-party collaborators for development and manufacturing.
- Forward-looking statements regarding cash runway and clinical milestones are subject to significant uncertainty.
Investor Verification Checklist
- Verify the Company's current cash position and runway, as the filing cites "financial challenges" but provides no specific liquidity data.
- Monitor the outcome of the strategic review process and any potential transaction announcements.
- Assess the feasibility and cost implications of the FDA-mandated randomized controlled trial design.
- Review the safety profile of PBFT02, specifically regarding the previously reported venous sinus thrombosis and hepatotoxicity events.
- Confirm the timeline for the next clinical data readout or strategic update, as the Company stated it will not provide updates until the Board approves a specific action.